ClinicalTrials.gg

Program

Estradiol

Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.

Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.

Furthest: phase 4, since Oct 8, 201255 company-led studies, 1 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk120 open or runningphase 4since Oct 8, 2012Apr 19, 2005none ahead
Bayer100 open or runningphase 4since Sep 12, 2005Sep 9, 2005none ahead
AbbVie80 open or runningphase 3since Feb 17, 2010Feb 17, 2010none ahead
Teva Pharmaceutical Industries30 open or runningphase 3since Nov 7, 2022Jul 2, 2010none ahead
TherapeuticsMD30 open or runningphase 3since Sep 5, 2013Sep 5, 2013none ahead
Grünenthal20 open or runningphase 1since Nov 9, 2018Nov 9, 2018none ahead
Merck20 open or runningphase 1since Nov 26, 2008Nov 26, 2008none ahead
Renovo20 open or runningphase 3since Jan 24, 2007Jan 24, 2007none ahead
Amneal Pharmaceuticals10 open or runningphase 3since Jan 28, 2013Jan 28, 2013none ahead
ascend-therapeutics10 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
biosante-pharmaceuticals10 open or runningphase 3since Oct 20, 2006Oct 20, 2006none ahead
centro-a-f-de-estudios-tecnologicos-s-a10 open or runningphase 3since Oct 16, 2008Oct 16, 2008none ahead
Corium Innovations11 open or runningphase 1since Aug 26, 2026Aug 26, 2026May 31, 2027phase 1 · NCT07794150
Hamad Medical10 open or runningphase 2since Apr 6, 2021Apr 6, 2021none ahead
Lotus Pharmaceutical10 open or runningphase 3since Dec 14, 2016Dec 14, 2016none ahead
Padagis10 open or runningphase 3since May 10, 2016May 10, 2016none ahead
prasco-llc10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
productos-cienti-ficos-s-a-de-c-v10 open or runningphase 1since Feb 10, 2011Feb 10, 2011none ahead
Sun Pharmaceutical Industries10 open or runningphase 3since Dec 15, 2012Dec 15, 2012none ahead
upsher-smith-laboratories10 open or runningphase 3since Jul 29, 2008Jul 29, 2008none ahead
viramal-limited10 open or runningphase 1since Jun 1, 2018Jun 1, 2018none ahead

Also a collaborator on its studies: iqvia-pty-ltd, Abbott, simbec-research, laboratoires-besins-international and gru-nenthal-s-a.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Apr 19, 2005.

  1. May 18, 2015Phase 2 study in DyspareuniaTherapeuticsMD · NCT02449902 · 50 enrolled · United States
  2. Jan 8, 2016Phase 3 study in LeiomyomaAbbVie · NCT02654054 · 413 enrolled · United States, Canada, Puerto Rico
  3. Feb 22, 2016Phase 3 study in LeiomyomaAbbVie · NCT02691494 · 378 enrolled · United States, Canada
  4. May 10, 2016Padagis's first study: phase 3 study in AtrophyNew to PadagisPadagis · NCT02770365 · 695 enrolled · United States
  5. Dec 14, 2016Lotus Pharmaceutical's first study: phase 3 study in Atrophic VaginitisNew to Lotus PharmaceuticalLotus Pharmaceutical · NCT02995694 · 535 enrolled
  6. Jul 7, 2017Phase 3 study in EndometriosisAbbVie · NCT03213457 · 681 enrolled · United States, Canada, Puerto Rico
  7. Aug 31, 2017Phase 3 study in MenorrhagiaAbbVie · NCT03271489 · 478 enrolled · United States, Puerto Rico
  8. Nov 1, 2017prasco-llc's first study: phase 3 study in PruritusNew to prasco-llcprasco-llc · NCT03332303 · 540 enrolled · United States
  9. Jun 1, 2018viramal-limited's first study: phase 1 study in MenopauseNew to viramal-limitedviramal-limited · NCT03556800 · 20 enrolled · United Kingdom
  10. Nov 9, 2018Grünenthal's first study: phase 1 study in BioequivalenceNew to GrünenthalGrünenthal · NCT03749733 · Mexico
  11. Apr 6, 2021Hamad Medical's first study: phase 2 study in COVID-19New to Hamad MedicalHamad Medical · NCT04853069 · 2,000 enrolled · Qatar
  12. Apr 5, 2022Phase 1 study in BioequivalenceGrünenthal · NCT05332106 · 10 enrolled · India
  13. Nov 7, 2022Phase 3 study in DyspareuniaTeva Pharmaceutical Industries · NCT05617820 · 1,050 enrolled · United States, El Salvador, Honduras
  14. Aug 26, 2026Corium Innovations's first study: phase 1 study in MenopauseNew to Corium InnovationsCorium Innovations · NCT07794150 · 250 planned · United States, India

Ahead

  1. May 31, 2027Primary completion: phase 1 study in MenopauseCorium Innovations · NCT07794150

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha agonist”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07794150Menopause · United States, India1RecruitingCorium InnovationsMay 31, 2027250
NCT05617820Dyspareunia · United States, El Salvador, Honduras3CompletedTeva Pharmaceutical IndustriesMar 15, 20241,050
NCT05332106Bioequivalence · India1CompletedGrünenthalMar 22, 202210
NCT04853069COVID-19 · Qatar2UNKNOWNHamad MedicalFeb 28, 20222,000
NCT03749733Bioequivalence · Mexico1WithdrawnGrünenthalDec 20190
NCT03556800Menopause · United Kingdom1UNKNOWNviramal-limitedJun 30, 202220
NCT03332303Pruritus · United States3Completedprasco-llcMar 15, 2018540
NCT03271489Menorrhagia · United States, Puerto Rico3CompletedAbbVieJun 28, 2024478
NCT03213457Endometriosis · United States, Canada, Puerto Rico3CompletedAbbVieMar 27, 2020681
NCT02995694Atrophic Vaginitis3CompletedLotus PharmaceuticalDec 2016535
NCT02770365Atrophy · United States3CompletedPadagisNov 2016695
NCT02691494Leiomyoma · United States, Canada3CompletedAbbVieFeb 14, 2018378
NCT02654054Leiomyoma · United States, Canada, Puerto Rico3CompletedAbbVieJan 18, 2018413
NCT02449902Dyspareunia · United States2CompletedTherapeuticsMDSep 201350
NCT02253173Dyspareunia · United States, Canada3CompletedTherapeuticsMDOct 2015764
NCT01942668Hot Flashes · United States3CompletedTherapeuticsMDOct 28, 20161,845
NCT01845649Dyspareunia · United States3CompletedAbbVieNov 20, 2013550
NCT01779947Atrophic Vaginitis Due to Menopause · United States3CompletedAmneal PharmaceuticalsSep 2012519
NCT01753102Vulvar Atrophy · India3TerminatedSun Pharmaceutical IndustriesApr 30, 201349
NCT01710696Genetic Diseases, Inborn · Spain3CompletedNovo NordiskJul 26, 200450
NCT01705249Menopause · Norway, Sweden4CompletedNovo NordiskJun 6, 2003191
NCT01638910Contraception · China, Hong Kong, India and more3CompletedBayerNov 2014955
NCT01596010Menopause · Germany1CompletedNovo NordiskNov 200744
NCT01486979Menopause · Germany1CompletedNovo NordiskMay 200758
NCT01477632Menopause · Germany1CompletedNovo NordiskJun 200524
NCT01455597Vulvovaginal Atrophy · United States3CompletedAbbVieDec 3, 2012309
NCT01400776Postmenopausal Vulvovaginal Atrophy · United States3CompletedAbbVieFeb 27, 2012722
NCT01293747Menopause · Mexico1Completedproductos-cienti-ficos-s-a-de-c-vAug 201130
NCT01181726Healthy · Canada1CompletedTeva Pharmaceutical IndustriesFeb 200740
NCT01157182Healthy · Canada1CompletedTeva Pharmaceutical IndustriesApr 200736
NCT01085877Menopause · Germany1CompletedNovo NordiskMay 201070
NCT01070979Hormone Replacement Therapy · United States3CompletedAbbVieSep 2003249
NCT00984386Cicatrix · United Kingdom2CompletedRenovoApr 200544
NCT00909857Primary Dysmenorrhea · United States, Canada, Chile and more3CompletedBayerNov 2010507
NCT00820664Postmenopausal Symptoms1CompletedMerckMay 200929
NCT00799708Postmenopause1CompletedMerckOct 200827
NCT00775242Hot Flashes · Mexico3Completedcentro-a-f-de-estudios-tecnologicos-s-aNov 2008103
NCT00754065Contraception · United States, Canada3CompletedBayerMay 10, 2011409
NCT00727129Hot Flashes3Completedupsher-smith-laboratories495
NCT00560924Menopause · Sweden3TerminatedNovo NordiskMar 17, 20046
NCT00522873Hot Flashes · United States, Argentina, Austria and more3CompletedBayerAug 2009662
NCT00465192Menopause3CompletedNovo NordiskNov 30, 1995230
NCT00464971Menopause3CompletedNovo NordiskNov 30, 1996102
NCT00446199Hot Flashes · United States3CompletedBayerOct 2008735
NCT00431132Menopause · Czech Republic, Denmark, Finland and more3CompletedNovo NordiskNov 2008336
NCT00426972Burns · Germany, Latvia, Russian Federation and more3CompletedRenovoJul 2008148
NCT00391417Hot Flashes3Completedbiosante-pharmaceuticals431
NCT00356447Vasomotor Symptoms · China3CompletedBayerOct 2007249
NCT00310531Bone Diseases, Metabolic3CompletedBayer500
NCT00184795Hot Flashes · Austria, Belgium, Denmark and more3CompletedNovo NordiskMay 4, 2005576
NCT00206622Hot Flashes · United States4CompletedBayer425
NCT00185328Postmenopause4CompletedBayer55
NCT00185237Hot Flashes3CompletedBayerNov 2006165
NCT00160173Postmenopausal Symptoms · United States4Completedascend-therapeuticsSep 6, 2005221
NCT00108849Menopause · United States, Canada3CompletedNovo NordiskMay 2007309

How it is read

Names in the registry

  • “Estradiol”, 7 entries
  • “NOMAC-E2”, 6 entries
  • “estradiol, 25 mcg”, 5 entries
  • “estradiol, 10 mcg”, 4 entries
  • “Zesteem”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.